Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48%

Rhea-AI Summary

Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported strong financial results for Q2 2024, with revenue increasing 48% to $29.9 million. The company's gross margin improved by 50 basis points to 62.1%. Despite a net loss of $3.9 million, Xtant achieved positive Adjusted EBITDA of $0.5 million.

Key highlights include the launch of two new amniotic membrane allograft products, signing 15 new distributors, and securing 20 IDN contracts. The company also entered a $5.0 million private placement to strengthen its balance sheet.

Xtant reaffirmed its 2024 revenue guidance of $116-$120 million, projecting 27-31% annual growth. The company expects continued momentum with new product launches, increased distributor penetration, and improved margins in the second half of 2024.

Positive

• Revenue increased 48% year-over-year to $29.9 million
• Gross margin improved by 50 basis points to 62.1%
• Achieved positive Adjusted EBITDA of $0.5 million
• Launched two new amniotic membrane allograft products
• Signed 15 new distributors and secured 20 IDN contracts
• Entered into a $5.0 million private placement to strengthen balance sheet
• Reaffirmed 2024 revenue guidance of $116-$120 million, projecting 27-31% annual growth

Negative

• Net loss increased to $3.9 million compared to $2.2 million in the year-ago quarter
• Operating expenses increased to $21.5 million from $13.9 million in Q2 2023
• Cash and cash equivalents decreased to $5.4 million from $5.7 million at the end of 2023
• Lingering supply chain challenges reported

Insights

Financial Analyst

Xtant Medical's Q2 2024 results show strong revenue growth of 48% year-over-year, reaching $29.9 million. This growth is primarily attributed to the acquisition of Surgalign Holdings' hardware and biologics business. The company's gross margin improved by 50 basis points to 62.1%, indicating better production efficiency.

However, the net loss widened to $3.9 million from $2.2 million in the previous year, mainly due to increased operating expenses. Positively, Adjusted EBITDA improved to $0.5 million from $0.1 million, marking the fifth consecutive quarter of positive Adjusted EBITDA.

The company's cash position remains tight at $5.4 million, but the announced $5 million private placement should provide some financial flexibility. Xtant's reaffirmed 2024 revenue guidance of $116-120 million suggests continued strong growth expectations.

Medical Device Industry Expert

Xtant's Q2 performance demonstrates solid market traction in the spinal disorder treatment sector. The launch of new amniotic membrane allograft products (SimpliGraft™ and SimpliMax™) and record sales for Cortera™ indicate successful product diversification and market acceptance.

The addition of 15 new distributors and 20 IDN contracts in Q2 suggests an expanding market reach and potential for sustained growth. However, the mention of lingering supply chain challenges is a concern, though the company is addressing this through self-produced products.

The focus on internally produced products could lead to improved margins and greater control over the supply chain, which is important in the medical device industry. The company's strategy of combining organic growth with strategic acquisitions appears to be yielding positive results, positioning Xtant well in the competitive spinal treatment market.

BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2024.

Second Quarter 2024 Financial Highlights

• Revenue of $29.9 million, up 48%, compared to the prior year quarter

• Gross margin of 62.1%, up 50 basis points, compared to the prior year quarter

• Net loss of $3.9 million compared to $2.2 million in the year ago quarter

• Positive Adjusted EBITDA; Adjusted EBITDA of $0.5 million compared to $0.1 million in the prior year quarter

Recent Business Highlights

• Recently launched two new amniotic membrane allografts products, SimpliGraft™ and SimpliMax™; while Cortera™ reached record sales and users for the second quarter

• Signed 15 new distributors in the second quarter

• Awarded 20 IDN contracts in the second quarter

• Entered into a $5.0 million private placement on August 7, 2024

Sean Browne, President and CEO of Xtant Medical, stated, "Our second quarter financial results illustrate the positive momentum that is building as we head into the second half of 2024. We delivered strong revenue growth, despite lingering supply chain challenges, which we are addressing through the launch of new, self-produced products. Furthermore, the second quarter marks our fifth consecutive quarter of positive Adjusted EBITDA, and our recent acquisitions are performing at or ahead of our expectations."

Browne continued, "We enter the second half of the year with significant business momentum and, after our recently announced private placement, a stronger balance sheet to support our strategic growth plans. In the second half of 2024, we expect additional new product launches, increased penetration within our distributor network, and an increase in the number of internally produced products, which will coalesce to drive further margin improvement on higher sales and generate positive operating cash flow. We are energized by the prospects for our business and remain committed to our mission of honoring the gift of donation by allowing our patients to live as full and complete a life as possible."

Second Quarter 2024 Financial Results

Total revenue for the three months ended June 30, 2024 was $29.9 million, an increase of 48% compared to $20.2 million in the prior year quarter. The increase is primarily due to the contribution of additional sales resulting from the acquisition of the Surgalign Holdings' hardware and biologics business.

Gross margin for the second quarter of 2024 was 62.1%, compared to 61.6% for the prior year quarter, an increase of 50 basis points. The increase is primarily due to greater scale and improved production efficiency, which was partially offset by increased charges for excess and obsolete inventory and non-absorbed costs and sales mix.

Operating expenses for the second quarter of 2024 totaled $21.5 million, compared to $13.9 million for the second quarter of 2023. The increase was primarily due to additional commission expense resulting from revenue growth, additional compensation expense related to additional headcount and additional stock-based compensation.

Net loss for the second quarter of 2024 was $3.9 million, or $(0.03) per share, compared to a net loss of $2.2 million, or $(0.02) per share in the year ago quarter.

Non-GAAP Adjusted EBITDA for the second quarter of 2024 was $0.5 million, compared to non-GAAP Adjusted EBITDA of $0.1 million for the prior-year period. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense and provision for income taxes, and as further adjusted to add back in or exclude, as applicable, non-cash compensation, acquisition-related expenses, acquisition-related fair value adjustments and foreign currency exchange gains. A calculation and reconciliation of Adjusted EBITDA to net loss can be found in the attached financial tables.

As of June 30, 2024, the Company had $5.4 million of cash and cash equivalents compared to $5.7 million as of December 31, 2023. In a separate release issued today, the Company announced it has entered into a securities purchase agreement with an existing institutional investor to sell $5.0 million shares of its common stock in a private placement at a purchase price of $0.64 per share.

2024 Financial Guidance

Xtant Medical reaffirms its expectation for full year 2024 revenue to $116 million to $120 million, which represents annual revenue growth of approximately 27% to 31% compared to full year 2023 revenue.

Conference Call

Xtant Medical will host a webcast and conference call to discuss second quarter 2024 financial results at 9:00 am ET on Friday, August 9, 2024.

To access the webcast, visit https://www.webcaster4.com/Webcast/Page/3039/50961

To access the conference call, dial 888-999-3182 within the U.S. or 848-280-6330 outside the U.S. Passcode: XTANT Medical Holdings.

A replay of the call will be available on the Investor section of the Company's website at www.xtantmedical.com.

About Xtant Medical Holdings, Inc.

Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Non-GAAP Financial Measures

To supplement the Company's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," ‘‘expects,'' ‘‘anticipates,'' ‘‘plans,'' ‘‘believes,'' ‘‘estimates,'' "continue," "future," ‘‘will,'' "potential," "going forward," "guidance," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company's financial guidance for 2024 and expectations for additional new product launches, further margin improvement on higher sales and the generation of positive operating cash flow. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's future operating results and financial performance; its ability to increase or maintain revenue; the Company's ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; risks associated with its acquisitions and the integration of those businesses; risk associated with its recently announced private placement; anticipated shortages of stem cells which will adversely affect future revenues; the Company's ability to implement successfully its future growth initiatives and risks associated therewith; possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory; the ability to remain competitive; the ability to innovate, develop and introduce new products and the success of those products; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company's dependence on key independent agents for a significant portion of its revenue; the effect of labor and hospital staffing shortages on the Company's business, operating results and financial condition, especially when they affect key markets; the effect of inflation, increased interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on the Company's financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; risks associated with the Company's clinical trials; international risks; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on April 1, 2024 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 anticipated to be filed with the SEC. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

Investor Relations Contact:

Brett Maas
Managing Partner, Hayden IR
brett@haydenir.com
(646) 536-7331

XTANT MEDICAL HOLDINGS, INC.
Condensed Consolidated Balance Sheets
(In thousands, except number of shares and par value)

		June 30, 2024				December 31, 2023
ASSETS
Current Assets:
Cash and cash equivalents		$	5,379			$	5,715
Restricted Cash			99				208
Trade accounts receivable, net of allowance for credit losses and doubtful accounts of $1,012 and $920, respectively			21,187				20,731
Inventories			40,507				36,885
Prepaid and other current assets			1,800				1,330
Total current assets			68,972				64,869
Property and equipment, net			8,837				8,692
Right-of -use asset, net			1,117				1,523
Goodwill			7,302				7,302
Intangible assets, net			9,220				10,085
Other assets			130				141
Total Assets		$	95,578			$	92,612
LIABILITIES & STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable		$	6,875			$	7,054
Accrued liabilities			8,676				10,419
Current portion of lease liability			794				830
Current portion of finance lease obligations			67				65
Line of credit			11,899				4,622
Total current liabilities			28,311				22,990
Long-term Liabilities:
Lease liability, less current portion			376				759
Finance lease obligations, less current portion			82				116
Long-term debt, plus premium and less issuance costs			21,770				17,167
Other liabilities			34				231
Total Liabilities			50,573				41,263
Stockholders' Equity
Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding			-				-
Common stock, $0.000001 par value; 300,000,000 shares authorized; 130,314,372 shares issued and outstanding as of June 30, 2024 and 130,180,031 shares issued and outstanding as of December 31, 2023			-				-
Additional paid-in capital			296,451				294,330
Accumulated other comprehensive (loss) income			(175	)			29
Accumulated deficit			(251,271	)			(243,010	)
Total Stockholders' Equity			45,005				51,349
Total Liabilities & Stockholders' Equity		$	95,578			$	92,612

XTANT MEDICAL HOLDINGS, INC.
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except number of shares and per share amounts)

		Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023
Revenue		$	29,943			$	20,232			$	57,816			$	38,176
Cost of sales			11,361				7,773				21,932				15,180
Gross Profit			18,582				12,459				35,884				22,996
Gross Profit %			62.1	%			61.6	%			62.1	%			60.2	%
Operating Expenses
General and administrative			7,713				4,954				15,498				9,839
Sales and marketing			13,179				8,716				25,639				15,770
Research and development			636				180				1,163				354
Total Operating Expenses			21,528				13,850				42,300				25,963
Loss from Operations			(2,946	)			(1,391	)			(6,416	)			(2,967	)
Other Expense
Interest expense			(992	)			(786	)			(1,827	)			(1,360	)
Interest income			-				-				-				85
Unrealized foreign currency translation loss			118				-				79				-
Other income			(5	)			-				7				-
Total Other Expense			(879	)			(786	)			(1,741	)			(1,275	)
Net Loss from Operations Before Provision for Income Taxes			(3,825	)			(2,177	)			(8,157	)			(4,242	)
Provision for Income Taxes
Current and Deferred			(36	)			(13	)			(104	)			(26	)
Net Loss		$	(3,861	)		$	(2,190	)		$	(8,261	)		$	(4,268	)
Net Loss Per Share:
Basic		$	(0.03	)		$	(0.02	)		$	(0.06	)		$	(0.04	)
Dilutive		$	(0.03	)		$	(0.02	)		$	(0.06	)		$	(0.04	)
Shares used in the computation:
Basic			130,269,710				108,897,048				130,291,796				108,895,327
Dilutive			130,269,710				108,897,048				130,291,796				108,895,327

XTANT MEDICAL HOLDINGS, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)

		Six Months Ended June 30,
		2024				2023
Operating activities:
Net loss		$	(8,261	)		$	(4,268	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			2,003				1,274
Gain on disposal of fixed assets			(142	)			(21	)
Non-cash interest			218				189
Stock-based compensation			2,138				1,056
Provision for reserve on accounts receivable			178				225
Provision for excess and obsolete inventory			388				243
Other			1				3
Changes in operating assets and liabilities, net of the effects of the acquisition:
Accounts receivable			(688	)			(3,116	)
Inventories			(4,130	)			(1,733	)
Prepaid and other assets			(469	)			(330	)
Accounts payable			(15	)			954
Accrued liabilities			(2,064	)			758
Net cash used in by operating activities			(10,843	)			(4,766	)
Investing activities:
Purchases of property and equipment			(1,337	)			(870	)
Proceeds from sale of fixed assets			183				55
Acquisition of Surgalign SPV, Inc.			-				(17,000	)
Net cash used in investing activities			(1,154	)			(17,815	)
Financing activities:
Payments on financing leases			(32	)			(30	)
Borrowings on line of credit			59,565				36,256
Repayments of line of credit			(52,288	)			(34,603	)
Proceeds from issuance of long term debt			5,000				5,000
Debt issuance costs			(615	)			(101	)
Payment of taxes from withholding of common stock on vesting of restricted stock units			(17	)			-
Net cash provided by financing activities			11,613				6,522
Effect of exchange rate changes on cash and cash equivalents and restricted cash			(61	)			-
Net change in cash and cash equivalents and restricted cash			(445	)			(16,059	)
Cash and cash equivalents and restricted cash at beginning of period			5,923				20,507
Cash and cash equivalents and restricted cash at end of period		$	5,478			$	4,448
Reconciliation of cash and restricted cash reported in the condensed consolidated balance sheets
Cash and cash equivalents		$	5,379			$	4,138
Restricted cash			99				310
Total cash and restricted cash reported in the condensed consolidated balance sheets		$	5,478			$	4,448

XTANT MEDICAL HOLDINGS, INC.
Calculation of Non-GAAP Consolidated EBITDA and Adjusted EBITDA
(Unaudited, in thousands)

		Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023
Net Loss		$	(3,861	)		$	(2,190	)		$	(8,261	)		$	(4,268	)
Depreciation and amortization			998				803				2,003				1,274
Interest expense			992				786				1,827				1,275
Tax expense			36				13				104				26
Non-GAAP EBITDA			(1,835	)			(588	)			(4,327	)			(1,693	)
Non-GAAP EBITDA/Total revenue			-6.1	%			-10.7	%			-7.5	%			-4.4	%
NON-GAAP ADJUSTED EBITDA CALCULATION
Non-cash compensation			1,228				439				2,138				1,056
Acquisition-related expenses			-				254				338				465
Acquisition-related fair value adjustments			1,229				-				2,530				-
Foreign currency exchange gain			(118	)			-				(79	)			-
Non-GAAP Adjusted EBITDA		$	504			$	105			$	600			$	(172	)

SOURCE: Xtant Medical Holdings, Inc.

View the original press release on accesswire.com

FAQ

What was Xtant Medical's (XTNT) revenue growth in Q2 2024?

Xtant Medical (XTNT) reported a revenue growth of 48% in Q2 2024, with total revenue reaching $29.9 million compared to $20.2 million in the prior year quarter.

How did Xtant Medical's (XTNT) gross margin change in Q2 2024?

Xtant Medical's (XTNT) gross margin improved by 50 basis points in Q2 2024, reaching 62.1% compared to 61.6% in the prior year quarter.

What is Xtant Medical's (XTNT) revenue guidance for full-year 2024?

Xtant Medical (XTNT) reaffirmed its full-year 2024 revenue guidance of $116 million to $120 million, representing an annual revenue growth of approximately 27% to 31% compared to 2023.

How many new distributors did Xtant Medical (XTNT) sign in Q2 2024?

Xtant Medical (XTNT) signed 15 new distributors in the second quarter of 2024.

What was Xtant Medical's (XTNT) Adjusted EBITDA for Q2 2024?

Xtant Medical (XTNT) reported a positive Adjusted EBITDA of $0.5 million for Q2 2024, compared to $0.1 million in the prior-year period.